Tfayli, H., Ulnach, J. W., Lee, S., Sutton-Tyrrell, K., & Arslanian, S. (2011). Drospirenone/Ethinyl Estradiol Versus Rosiglitazone Treatment in Overweight Adolescents with Polycystic Ovary Syndrome: Comparison of Metabolic, Hormonal, and Cardiovascular Risk Factors. Endocrine Society.
Styl ChicagoTfayli, Hala, Julia Warren Ulnach, SoJung Lee, Kim Sutton-Tyrrell, a Silva Arslanian. Drospirenone/Ethinyl Estradiol Versus Rosiglitazone Treatment in Overweight Adolescents With Polycystic Ovary Syndrome: Comparison of Metabolic, Hormonal, and Cardiovascular Risk Factors. Endocrine Society, 2011.
Citace podle MLATfayli, Hala, et al. Drospirenone/Ethinyl Estradiol Versus Rosiglitazone Treatment in Overweight Adolescents With Polycystic Ovary Syndrome: Comparison of Metabolic, Hormonal, and Cardiovascular Risk Factors. Endocrine Society, 2011.